Loading...
NPI 1427161710 · Great Neck, NY · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Brett Rosenblatt is a ophthalmology physician provider located in Great Neck, New York. This profile covers 25 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Brett Rosenblatt |
| Address | 600 Northern Blvd |
| City | Great Neck |
| State | NY |
| ZIP | 11021 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | August 17, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.5M |
| Medicaid | $9.3K |
Practice concentration in retina therapeutics and diagnostics: Medicare billing is heavily weighted toward intravitreal drug administration and posterior-segment imaging, with J0178 (injection, aflibercept) alone responsible for $2.6M revenue (47.8% of this provider's total Medicare revenue) and large reported claim volume (3.8K claims). High utilization of newer and biosimilar anti-VEGF agents is also visible in the top codes (J2777 and Q5128), which together with J0178 form the primary revenue drivers for Medicare. This mix indicates an operational model built around frequent in-office injections and supporting imaging services rather than general ophthalmic outpatient care.
Medicare revenue is highly concentrated: the precomputed top 3 Medicare codes account for 69.5% of the provider's Medicare revenue, signaling reliance on a small set of high-value treatment codes (notably J0178, J2777, Q5128). That concentration makes the practice sensitive to utilization shifts or pricing changes for these intravitreal drugs. Operationally, sustaining volume on those specific codes appears critical to overall Medicare revenue performance.
Medicaid footprint is negligible compared with Medicare: lifetime Medicare revenue is $5.5M while lifetime Medicaid revenue is $9.3K, so the provider operates effectively as a Medicare-centered practice. On Medicaid the top codes (including 67028 and 92134) account for 100.0% of Medicaid revenue, but the absolute Medicaid dollar scale is orders of magnitude smaller than Medicare, limiting Medicaid’s operational significance to the business profile.
National competitive standing is strong for select Medicare services: J0178 ranks #84 of 3204 providers nationally (97th percentile; notably above typical national volume for this code), and 67028 ranks #90 of 4255 (98th percentile; notably above typical national volume for this code). The provider is an outlier in diagnostic imaging as well—92134 registers 4.7K claims with $174.2K revenue (3.2% of Medicare revenue) and ranks #65 of 26868 providers nationally (100th percentile; extreme outlier), indicating unusually high imaging throughput compared with peers.
For many other codes the provider’s volumes are typical or modest: J2777 ranks #509 of 2039 (75th percentile; typical, unremarkable volume), Q5128 ranks #45 of 373 (88th percentile; typical, unremarkable volume), and multiple evaluation-and-management and ancillary procedure codes show high percentiles of claims but generally reflect standard ophthalmic workflows. This pattern suggests dominance in a few procedural niches while maintaining routine outpatient and diagnostic services at expected levels.
State-level Medicaid competitiveness is modest: 67028 is #180 of 262 providers in-state (31st percentile; typical, unremarkable volume) and 92134 is #324 of 728 in-state (56th percentile; typical, unremarkable volume), indicating the provider is not a dominant Medicaid retinal-service provider within New York despite the code mix matching a retina-focused practice. Those in-state ranks contrast with the stronger national Medicare standing on several retinal codes.
Operational implications from the code mix include sustained in-office injection capacity and advanced imaging infrastructure: repeated high-volume billing for J0178 (3.8K claims) plus an extreme outlier level of 92134 (4.7K claims) implies established clinical workflows for frequent intravitreal injections and same-day or bundled retinal imaging and interpretation. Payers evaluating network adequacy or specialty access should expect this provider to deliver frequent anti-VEGF and imaging services rather than broad-spectrum ophthalmology care.
Long-tenure credentialing and stability: the NPI was enumerated on 2006-08-17 (~20 years ago), indicating a long-established presence in the market that aligns with the high cumulative Medicare volume and concentrated, repeat-treatment service lines. That tenure supports expectations of established referral patterns and operational stability for retina-focused procedures.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
25 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 3,810 | $690 | $2.6M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 20,520 | $30 | $595.1K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 2,720 | $220 | $586.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 3,080 | $110 | $342.1K |
| J2778 | Injection, ranibizumab, 0.1 mg | 1,620 | $180 | $293.9K |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 1,290 | $170 | $223.6K |
| J3490 | Unclassified drugs | 90 | $2,060 | $185.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 4,710 | $40 | $174.2K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 1,490 | $80 | $117.4K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,150 | $80 | $89.9K |
Showing 1–10 of 25
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 25 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
25 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 6 | 230 | 560 | $690 | $693K |
| J2777 | 19 | 120 | 7,740 | $30 | $364.9K |
| Q5128 | 3 | 20 | 1,170 | $220 | $268.3K |
| J2778 | 6 | 70 | 510 | $180 | $131.6K |
| J2781 | 14 | 40 | 520 | $120 | $75.1K |
| Q5124 | 1 | 20 | 310 | $170 | $69.7K |
| 67028 | 2 | 300 | 400 | $100 | $65.9K |
| J3490 | 41 | 120 | 60 | $470 | $50.8K |
| 92014 | 601 | 2,220 | 160 | $100 | $29.3K |
| 67036 | 46 | 50 | 20 | $940 | $23.5K |
Showing 1–10 of 25
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 150 | $30 | $4.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 550 | $10 | $4.4K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 10 | $10 | $80 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 1,405 | 1,460 | 310 | $60 | $88.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 180 | 260 | 420 | $70 | $65.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 324 | 730 | 370 | $20 | $30K |
Other providers in the same ZIP code as Brett Rosenblatt, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| C And T Homecare Services LLC | NY | In Home Supportive Care Agency | $0 | $847.7M |
| North Shore-lij Medical PC | NY | Urology Physician | $0 | $388.1M |
| First Choice Home Care Inc | NY | Home Health Agency | $0 | $28M |
| Welllife Network Inc. | NY | Clinic/Center | $0 | $22M |
| Regioncare Inc. | NY | Home Infusion Agency | $40.1K | $9.4M |
| Philip Ferrone | NY | Ophthalmology Physician | $3.1M | $10.5K |
| Shahram Shamekh | NY | Internal Medicine Physician | $673.3K | $1.4M |
| Angela Azar | NY | Dermatology Physician | $104.5K | $1.5M |
| Alireza Shirvani | NY | Hospitalist Physician | $1.4M | $178K |
| Stephanie Buck-haskin | NY | Obstetrics & Gynecology Physician | $56.1K | $1.4M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.